Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

被引：0
|
作者：
N. M. Atallah
M. Alsaleem
M. S. Toss
N. P. Mongan
E. Rakha
机构：
[1] the University of Nottingham and Nottingham University Hospitals NHS Trust,Division of Cancer and Stem Cells, School of Medicine
[2] Menoufia University,Department of Pathology, Faculty of Medicine
[3] Qassim University,Unit of Scientific Research, Applied College
[4] Sheffield Teaching Hospitals NHS Foundation Trust,Histopathology Department, Royal Hallamshire Hospital
[5] University of Nottingham,School of Veterinary Medicine and Sciences
[6] Weill Cornell Medicine,Department of Pharmacology
来源：
British Journal of Cancer | 2023年 / 129卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1692 / 1705
页数：13
相关论文
共 50 条
  • [21] HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Hou, Yanjun
    Nitta, Hiroaki
    Wei, Lai
    Banks, Peter M.
    Portier, Bryce
    Parwani, Anil V.
    Li, Zaibo
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (02) : 447 - 457
  • [22] HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Yanjun Hou
    Hiroaki Nitta
    Lai Wei
    Peter M. Banks
    Bryce Portier
    Anil V. Parwani
    Zaibo Li
    Breast Cancer Research and Treatment, 2017, 166 : 447 - 457
  • [23] HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
    Novillo, Apolonia
    Gaibar, Maria
    Romero-Lorca, Alicia
    Malon, Diego
    Anton, Beatriz
    Moreno, Amalia
    Fernandez-Santander, Ana
    CANCERS, 2023, 15 (03)
  • [24] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    LABORATORY INVESTIGATION, 2018, 98 : 91 - 91
  • [25] Decreased HER2 expression in endometrial cancer following anti-HER2 therapy
    Chui, M. Herman
    Brown, David N.
    Paula, Arnaud Da Cruz
    da Silva, Edaise M.
    Momeni-Boroujeni, Amir
    Reis-Filho, Jorge S.
    Zhang, Yanming
    Makker, Vicky
    Ellenson, Lora Hedrick
    Weigelt, Britta
    JOURNAL OF PATHOLOGY, 2024, 262 (02): : 129 - 136
  • [26] HER2-positive breast cancer: From trastuzumab to innovatory anti-HER2 strategies
    Whenham, Nicolas
    D'Hondt, Veronique
    Piccart, Martine J.
    CLINICAL BREAST CANCER, 2008, 8 (01) : 38 - 49
  • [27] Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
    Yan, Hui
    Xiao, Hui
    Zhu, Jiujun
    Zhang, Jingyang
    Liu, Zhenzhen
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12715 - 12722
  • [28] Targeting the mevalonate pathway in HER2-positive breast cancer to overcome resistance to anti-HER2 therapy
    Sethunath, Vidyalakshmi
    Hu, Huizhong
    De Angelis, Carmine
    Veeraraghavan, Jamunarani
    Qin, Lanfang
    Rimawi, Motthaffar F.
    Osborne, Kent C.
    Schiff, Rachel
    CANCER RESEARCH, 2018, 78 (04)
  • [29] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    CANCER RESEARCH, 2022, 82 (04)
  • [30] Clinicopathological Factors Predicting Pathological Complete Response to Neoadjuvant Anti-HER2 Therapy in HER2-Positive Breast Cancer
    Jung, Youn Joo
    Lee, Seungju
    Kang, Seok Kyeong
    Kim, Jee Yeon
    Choo, Ki Seok
    Nam, Kyung Jin
    Joo, Ji Hyeon
    Kim, Jae Joon
    Kim, Hyun Yul
    ONCOLOGY, 2024,
12345